Sign In
Buy RVMD
$183.95
-2.93 (-1.57%)
At Close: Jul 13, 2026
5 Stock Setups Where Wall Street Sees the Most Upside Right Now
10:44pm, Sunday, 12'th Jul 2026
The S&P 500 is up 10.3% YTD, and Wall Street is convinced the markets have more room to run, particularly for this group of stocks we have uncovered. JPMorgan just tagged CECO Environmental (NASDAQ: C
Better Growth Buy: Axsome vs Revolution Medicines
03:55am, Thursday, 09'th Jul 2026
Axsome has a solid late-stage pipeline and growing commercialized drugs. Revolution aims to revolutionize cancer treatment, and a recent phase 3 trial shows it may be on the right path.
European Medicines Agency Expedites Assessment of Revolution Medicines' Daraxonrasib Under Phased Review Process
09:23am, Tuesday, 07'th Jul 2026
REDWOOD CITY, Calif., July 07, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted c
EMA fast-tracks review of Revolutions' experimental pancreatic cancer pill
09:09am, Tuesday, 07'th Jul 2026
The European Medicines Agency said on Tuesday it has begun a rolling review of Revolution Medicines' experimental treatment for patients with metastatic pancreatic cancer.
These 3 Stocks Trounced the S&P 500 in the First Half of 2026 -- and Wall Street Thinks 1 of Them Could Soar Even More
06:10pm, Monday, 06'th Jul 2026
Each of these biotech players has reached an important turning point. Recent drug approvals could supercharge the performance of one in particular.
Revolution Medicines Is Up Nearly 140% in 2026. Is the Hot Biotech Stock Still a Buy?
07:15pm, Sunday, 05'th Jul 2026
Revolution Medicines has taken a new approach to the treatment of certain cancers. The company's lead product is approaching the regulatory review stage.
REDWOOD CITY, Calif., July 02, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted c
Revolution Medicines Has a $40 Billion Market Cap and Generates No Revenue. Here's Why That's Not Absurd.
04:37pm, Wednesday, 01'st Jul 2026
Revolution Medicines' cancer drugs in development could establish new standards of care in some niches. The biotech company may launch its leading candidate within the next year.
REDWOOD CITY, Calif., June 24, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announc
RVMD Starts Treatment in Phase III Pancreatic Cancer Study on Zoldonrasib
11:16am, Wednesday, 24'th Jun 2026
Revolution Medicines launches a phase III study of zoldonrasib plus chemotherapy in first-line metastatic PDAC harboring RAS G12D mutations.
After Apogee, 3 More Biotech Buyout Targets Wall Street Can't Stop Watching
07:55am, Wednesday, 24'th Jun 2026
Biotech M&A is back in the spotlight. Big Pharma faces patent cliffs over the next several years, and recent dealmaking, including the AbbVie (NYSE: ABBV | ABBV Price Prediction) acquisition of Apogee
Revolution Medicines Announces Planned Leadership Transition for Steve Kelsey, M.D.
08:00am, Monday, 22'nd Jun 2026
Steve Kelsey, president, R&D, to transition to senior advisor to CEO ahead of planned retirement in January 2027 Company announces new R&D leadership structure to support continued execution of strate
Revolution Medicines: Strong Data, Big Market (Rating Upgrade)
05:04am, Saturday, 13'th Jun 2026
Revolution Medicines is upgraded to buy as Daraxonrasib delivers practice-changing Phase 3 data in pancreatic ductal adenocarcinoma (PDAC). RVMD's $4B pro forma liquidity supports over two years of ag
Can Revolution Medicines Be a Game-Changer Stock?
06:45am, Thursday, 11'th Jun 2026
Revolution Medicines' promising pancreatic cancer therapy could be approved later this year. The clinical-stage company has more than $4 billion in cash to develop and market its drugs.
Why Is Revolution Medicines (RVMD) Up 9.3% Since Last Earnings Report?
12:35pm, Friday, 05'th Jun 2026
Revolution Medicines (RVMD) reported earnings 30 days ago. What's next for the stock?
